


# Ginsenoside Rg3 Mitigates LPS-Induced Injury in Human Bronchial Epithelial Cells by Restoring Autophagic Flux and Inhibiting the TLR4/NF- $\kappa$ B-Mediated Inflammatory Response

## Supplementary Figures


**Figure S1: G-Rg3 Regulates AMPK/mTOR Signaling Pathway Activation in LPS-Induced Inflammatory Models**

(A) AMPK, (B) p-AMPK, (C) mTOR, and (D) p-mTOR. Cells were assigned to five treatment groups: control (Ctrl), ginsenoside Rg3 (Rg3), lipopolysaccharide (LPS), LPS + Rg3, and LPS + Rg3 + compound C (LPS+Rg3+CC); protein expression was detected via Western blot, with GAPDH (~37 kDa) as the loading control.



**Figure S2: G-Rg3 Regulates NF- $\kappa$ B Signaling Pathway-Related Protein Expression in LPS-Induced Inflammatory Models**

(A) *p-p65*, (B) *p65*, and (C) *I $\kappa$ B $\alpha$* . Cells were assigned to five treatment groups: control (*Ctrl*), ginsenoside *Rg3* (*Rg3*), lipopolysaccharide (*LPS*), *LPS + Rg3*, and *LPS + Rg3 + compound C* (*LPS+Rg3+CC*); protein expression was detected via Western blot with corresponding loading controls.



**Figure S3: G-Rg3 Regulates Autophagy-Related Protein Expression in LPS-Induced Models (Including ATG5 Knockdown Intervention)**

(A) ATG5, (B) LC3-II/I, (C) LC3-II/I, (D) SQSTM1/p62, (E) SQSTM1/p62. Cells were assigned to different treatment groups: For panels A, B, D: control (Ctrl), negative control siRNA (si-NC), ATG5-targeting siRNA (si-ATG5), lipopolysaccharide (LPS), LPS + ginsenoside Rg3 (LPS+Rg3), LPS+Rg3+si-ATG5; For panels C, E: Ctrl, Rg3, LPS, LPS+Rg3, LPS+Rg3+compound C (LPS+Rg3+CC). Protein expression was detected via Western blot with corresponding loading controls

